Stock Taper
| DATE | TYPE | RATIO |
|---|---|---|
| 2023-08-17 | Reverse | 2:3 |
| 2022-04-19 | Reverse | 1:50 |
| 2018-12-14 | Reverse | 1:15 |
| 2016-08-29 | Reverse | 1:10 |
| 2016-08-19 | Reverse | 1:10 |
| 2014-06-30 | Reverse | 1:100 |
| 2014-03-10 | Reverse | 1:100 |
| 2005-08-03 | Reverse | 1:400 |
CervoMed Inc. is a Boston-based clinical-stage biotech developing neflamapimod, an oral drug for neurodegenerative diseases like DLB, Alzheimer's, and stroke recovery.

Neflamapimod, CervoMed's lead oral drug candidate, is an investigational treatment targeting synaptic dysfunction to potentially modify age-related neurodegenerative disorders like DLB and FTD.
Overall rating: C
| PEER | PRICE | |
|---|---|---|
ADAG | $3.68 | COMPARE |
FBIO | $2.77 | COMPARE |
ACET | $9.06 | COMPARE |
VTVT | $32.36 | COMPARE |
GANX | $1.77 | COMPARE |
OSTX | $1.64 | COMPARE |
XBIT | $2.27 | COMPARE |
NRXP | $3.55 | COMPARE |